Odisha-based Serendipity Space, a pioneering space-tech company developing microgravity-based pharmaceutical manufacturing solutions, has raised its pre-seed round from Campus Fund.
The investment will accelerate the company's mission to transform drug development by leveraging space-based crystallisation technology through its proprietary satellite platform and autonomous pharmaceutical crystallization module called ‘Alchemy’.
Serendipity Space addresses one of the pharmaceutical industry's biggest bottlenecks - the inability to produce high-quality protein and drug crystals on Earth due to gravity-induced defects. The team combines deep space systems engineering expertise with pharmaceutical development experience by witnessing how microgravity-produced drugs like Keytruda transformed cancer treatment.
Since inception, the company has built and tested multiple functional pharmaceutical modules, including two crystallisation modules and one formulation module. Their ground-based validation of the autonomous pharmaceutical module with proteins and small molecules has demonstrated laboratory-grade crystallization quality.
Space-based pharmaceutical production can yield an average net present value (NPV) of $1.2 billion per novel drug for a pharmaceutical company and the broader in-space manufacturing market is projected to surpass $10 billion by 2030, driven by the unique advantages provided by the microgravity environment.
With the funding, Serendipity Space plans to execute technical demonstrations that shall validate the core subsystems required to deploy this technology as an end to end service for pharmaceutical companies. Serendipity Space joins Campus Fund's growing portfolio of deep-tech ventures reimagining India's position in cutting-edge industries, from space technology to advanced manufacturing, driven by student entrepreneurs building the future of innovation.
